Overview

Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

This study is a prospective, single-center, single-arm exploratory clinical study, aiming to complete the preliminary clinical observation of 12 children with relapsed/refractory acute myeloid leukemia treated with JK500 cell injection to evaluate the safety of clinical infusion and the initial efficacy of JK500 cell injection in the treatment of children with relapsed/refractory acute myeloid leukemia.

Phase:

Early Phase 1

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Collaborators:

Bejing Institute for Stem Cell and Regenerative Medicine
Institute for Stem cell and Regeneration, Chinese Academy of Sciences

Treatments:

Cyclophosphamide
Fludarabine